Thermo Fisher Scientific (NYSE:TMO) Hits New 12-Month High – Should You Buy?

Thermo Fisher Scientific Inc. (NYSE:TMO) reached a new 52-week high during trading on Wednesday . The stock traded as high as $648.44 and last traded at $640.6360, with a volume of 228048 shares changing hands. The stock had previously closed at $641.39.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on TMO. KeyCorp reissued an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. UBS Group upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and upped their price objective for the company from $540.00 to $730.00 in a report on Tuesday, September 8th. HSBC upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 1st. Barclays upped their price target on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Finally, BMO Capital Markets downgraded shares of Thermo Fisher Scientific to a “market perform” rating in a research report on Wednesday, September 9th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $624.64.

Thermo Fisher Scientific Price Performance

The firm has a market capitalization of $237.07 billion, a P/E ratio of 34.50, a PEG ratio of 2.57 and a beta of 0.85. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The business’s 50 day moving average is $584.82 and its 200-day moving average is $520.14.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter in the prior year, the business earned $4.28 earnings per share. The business’s revenue for the quarter was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

Insider Activity

In other news, CAO Joseph Holmes sold 420 shares of the company’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the sale, the chief accounting officer directly owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael Shafer sold 25,500 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the sale, the executive vice president owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. The trade was a 54.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 73,768 shares of company stock worth $44,122,820. 0.33% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Anchor Investment Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 31.2% in the second quarter. Anchor Investment Management LLC now owns 8,232 shares of the medical research company’s stock valued at $4,127,000 after purchasing an additional 1,960 shares in the last quarter. ABS Direct Equity Fund LLC bought a new stake in Thermo Fisher Scientific during the second quarter worth $251,000. Rench Wealth Management Inc. raised its position in Thermo Fisher Scientific by 17.6% in the 2nd quarter. Rench Wealth Management Inc. now owns 2,906 shares of the medical research company’s stock valued at $1,457,000 after buying an additional 434 shares during the last quarter. Bouchey Financial Group Ltd. bought a new position in Thermo Fisher Scientific during the 2nd quarter valued at $205,000. Finally, Van Hulzen Asset Management LLC purchased a new position in Thermo Fisher Scientific during the 2nd quarter worth $260,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.